Azanthranylalkyl and -cycloalkyl amides and their use as VEGF receptor inhibitors

A compound of the formula

• in which
• A is the group —NR7;
• W is oxygen or sulfur,
• Z is a bond,
• R1 is branched or unbranched C1-12alkyl or C2-12alkenyl which is optionally substituted once or many times by halogen, hydroxy, C1-6alkyloxy, aralkyloxy, C1-6alkyl and/or NR11R12;
• X is C1-6alkyl;
• R2 signifies pyridyl;
• R3, R4, R5 and R6 are hydrogen, halogen;
• or C1-6alkoxy, C1-6alkyl, C1-6carboxyalkyl either unsubstituted or optionally substituted once or many times by halogen;
• R7 is hydrogen, C1-6alkyl or C1-8cycloalkyl;
• R8, R9 and R10 are hydrogen or C1-6alkyl;
• and
• R11 and R12 are hydrogen or C1-6alkyl or form a ring which may contain a further hetero atom and may be optionally substituted by C1-6alkyl,
• except those compounds,
• in which
• W is oxygen;
• Z is a bond;
• X is C2alkyl;
• R2 signifies unsubstituted 4-pyridyl;
• R3, R4, R6, R7 and R9 are, respectively, hydrogen;
• R5 is hydrogen or chlorine;
• and
• R1 signifies n-propyl, cyclopropyl or allyl,
• and the salts thereof.